Advances in systemic therapies for metastatic castration-resistant prostate cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Future Oncology

• Publication date

  2014-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.14.128PMID 25471035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

  2014cited by this paper
• Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

  2014cited by this paper
• Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

  2014cited by this paper
• Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

  2014cited by this paper
• Challenges and recommendations for early identification of metastatic disease in prostate cancer.

  2014cited by this paper
• Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study.

  2014cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer

  2013cited by this paper
• Castration-resistant prostate cancer: AUA Guideline.

  2013cited by this paper
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

  2013cited by this paper
• Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

  2013cited by this paper
• Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms

  2013cited by this paper
• Intermittent versus continuous androgen deprivation in prostate cancer.

  2013cited by this paper
• Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

  2013cited by this paper
• Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• The utility of prostate‐specific antigen in the management of advanced prostate cancer

  2013cited by this paper
• Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

  2012cited by this paper
• Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

  2012cited by this paper
• Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• ARN-509: a novel antiandrogen for prostate cancer treatment.

  2012cited by this paper
• The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

  2012cited by this paper
• Androgen deprivation therapy and competing risks.

  2011cited by this paper
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

  2011cited by this paper
• A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

  2011cited by this paper
• Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients

  2011cited by this paper
• From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• Unravelling the role of denosumab in prostate cancer.

  2011cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Whole-cell vaccines: A failure or a success waiting to happen?

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Effective testosterone suppression for prostate cancer: is there a best castration therapy?

  2009cited by this paper
• Cytotoxic compounds in the treatment of castration-resistant prostate cancer.

  2009cited by this paper
• The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

  2008cited by this paper
• Antiandrogen withdrawal in castrate‐refractory prostate cancer

  2008cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  2008cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  2003cited by this paper
• Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

  2003cited by this paper
• Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

  2002cited by this paper
• Androgen Receptor Phosphorylation

  2002cited by this paper
• The potential role of bisphosphonates in prostate cancer

  2002cited by this paper
• EAU guidelines on prostate cancer.

  2001cited by this paper
• Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.

  2000cited by this paper
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

  1998cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• New therapeutic agents for hormone-refractory prostate cancer.

  1996cited by this paper
• Androgen receptor phosphorylation.

  1996cited by this paper
• Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

  1995cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Bone metastases: improving the therapeutic index.

  1994cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

  1984cited by this paper

• A Review of Sipuleucel-T in Combination with Other Therapies for Metastatic Castration-Resistant Prostate Cancer

  2025cites this paper
• Durable responses to frontline 177Lu-PSMA radioligand therapy in patients with metastatic castration resistant prostate cancer (mCRPC)

  2025cites this paper
• Induction of apoptosis in prostate cancer by ginsenoside Rh2

  2018cites this paper
• MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer

  2018cites this paper
• Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway.

  2016cites this paper